Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE study of subcutaneous versus intravenous dostarlimab with carboplatin-paclitaxel in advanced or recurrent endometrial cancer
jRCT2031260609Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Nov 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of dostarlimab, carboplatin and paclitaxel in endometrial cancer (EC) (4 arms), sponsored by GSK. Primary endpoints: Part 1: Serum trough concentration after first dose, Part 1: Area under the concentration-time curve and 3 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
dostarlimabcarboplatinpaclitaxel
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2031260609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260609.